EURICAN P

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

CANINE PARVOVIRUS ATTENUATED

Inapatikana kutoka:

Merial Animal Health Limited

ATC kanuni:

QI07AD01

INN (Jina la Kimataifa):

CANINE PARVOVIRUS ATTENUATED

Kipimo:

Unknown

Dawa fomu:

Lyophilisate for suspension

Dawa ya aina:

POM

Kundi la matibabu:

Canine

Eneo la matibabu:

Canine parvovirus vaccine

Matibabu dalili:

Immunological - Live Vaccine

Idhini hali ya:

Authorised

Idhini ya tarehe:

2004-11-03

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican P.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose of vaccine contains:
Freeze-dried pellet:
Attenuated canine parvovirus
>10
4.9
CCID
50
Excipients
q.s. 1 dose
For full list of excipients, see section 6.1.
CCID
50
= 50% cell culture infective dose.
3 PHARMACEUTICAL FORM
Lyophilisate for suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and puppies from 8 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs from 8 weeks of age to prevent clinical signs and to reduce mortality and viral excretion
caused by canine parvovirosis infection.
Onset of immunity: 7 days after primary vaccination
Duration of immunity: 2 years.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 25/05/2012_
_CRN 7012354_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
The CPV vaccine strain of Eurican P may be shed from vaccinated animals for a number of days following vaccination.
However, due to the absence of pathogenicity of the strain, it is not necessary to keep vaccinated animals separated
from non-vaccinated animals.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS:
In the case of accidental self injection, seek medical advice immediately and show this package insert or the label to the
physican.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
In rare cases, slight and transient pain may be apparent at the time of injection, which regresses within 2 hours.
In exceptional circumstances a hypersensitivity�